References
1. Gilstrap LC, Christensen R, Clewell WH, et al. Effect of
Corticosteroids for Fetal Maturation on Perinatal Outcomes: NIH
Consensus Development Panel on the Effect of Corticosteroids for Fetal
Maturation on Perinatal Outcomes. JAMA. 1995;273(5):413-418.
2. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating
fetal lung maturation for women at risk of preterm birth. Cochrane
Database Syst Rev. 2006;(3):CD004454.
3. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids
for accelerating fetal lung maturation for women at risk of preterm
birth. Cochrane Database Syst Rev. 2017;3:CD004454.
4. Skoll A, Boutin A, Bujold E, et al. No. 364-Antenatal Corticosteroid
Therapy for Improving Neonatal Outcomes. J Obstet Gynaecol Can.
2018;40(9):1219-1239.
5. ACOG. American College of Obstetricians and Gynecologists’ Committee
on Practice Bulletins—Obstetrics. Practice Bulletin No. 171:
Management of Preterm Labor. Obstet Gynecol. 2016;128(4):e155-164.
6. WHO. World Health Organization. Recommendations on Interventions to
Improve Preterm Birth Outcomes.; 2015.
7. National Institute for Health and Care Excellence. Preterm Labour and
Birth. NICE Guideline NG25.; 2015.
8. Marleen S, Hettiarachchi J, Dandeniya R, et al. Maternal clinical
predictors of preterm birth in twin pregnancies: A systematic review
involving 2,930,958 twin pregnancies. European Journal of Obstetrics &
Gynecology and Reproductive Biology. 2018;230:159-171.
9. Lee YM. Delivery of Twins. Seminars in Perinatology.
2012;36(3):195-200.
10. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ,
Morrison JC. Use of antenatal corticosteroids in special circumstances:
a comprehensive review. Acta Obstet Gynecol Scand. 2017;96(4):395-409.
11. Ballabh P, Lo ES, Kumari J, et al. Pharmacokinetics of betamethasone
in twin and singleton pregnancy. Clin Pharmacol Ther. 2002;71(1):39-45.
12. Koren G, Pariente G. Pregnancy- Associated Changes in
Pharmacokinetics and their Clinical Implications. Pharm Res.
2018;35(3):61.
13. Ansari J, Carvalho B, Shafer SL, Flood P. Pharmacokinetics and
Pharmacodynamics of Drugs Commonly Used in Pregnancy and Parturition.
Anesth Analg. 2016;122(3):786-804.
14. Tan EK, Tan EL. Alterations in physiology and anatomy during
pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology.
2013;27(6):791-802.
15. Petersen MC, Ashley JJ, McBride WG, Nation RL. Disposition of
betamethasone in parturient women after intramuscular administration. Br
J Clin Pharmacol. 1984;18(3):383-392.
16. Petersen MC, Nation RL, Ashley JJ. Simultaneous determination of
betamethasone, betamethasone acetate and hydrocortisone in biological
fluids using high-performance liquid chromatography. J Chromatogr.
1980;183(2):131-139.
17. Ke AB, Milad MA. Evaluation of Maternal Drug Exposure Following the
Administration of Antenatal Corticosteroids During Late Pregnancy Using
Physiologically-Based Pharmacokinetic Modeling. Clin Pharmacol Ther.
2019;106(1):164-173.
18. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on
CYP3A and P-glycoprotein activities as measured by disposition of
midazolam and digoxin: a University of Washington specialized center of
research study. Clin Pharmacol Ther. 2008;84(2):248-253.
19. Foissac F, Zheng Y, Hirt D, et al. Maternal betamethasone for
prevention of Respiratory Distress Syndrome in neonates: population
pharmacokinetic and pharmacodynamic approach. Clinical Pharmacology &
Therapeutics. 2020;n/a(n/a).
20. Jobe AH, Milad MA, Peppard T, Jusko WJ. Pharmacokinetics and
Pharmacodynamics of Intramuscular and Oral Betamethasone and
Dexamethasone in Reproductive Age Women in India. Clin Transl Sci.
2020;13(2):391-399.
21. Salem I I, Najib N. Pharmacokinetics of betamethasone after
single-dose intramuscular administration of betamethasone phosphate and
betamethasone acetate to healthy subjects. Clinical Therapeutics.
2012;34(1).
22. Della Torre M, Hibbard JU, Jeong H, Fischer JH. Betamethasone in
pregnancy: influence of maternal body weight and multiple gestation on
pharmacokinetics. American Journal of Obstetrics and Gynecology.
2010;203(3):254.e1-254.e12.
23. Petersen MC, Nation RL, McBride WG, Ashley JJ, Moore RG.
Pharmacokinetics of betamethasone in healthy adults after intravenous
administration. Eur J Clin Pharmacol. 1983;25(5):643-650.
24. Camelo Júnior JS, Martinez FE, Jorge SM, de Sala MM. A new method
for sampling maternal blood in the placental intervillous space. Fetal
Diagn Ther. 1995;10(5):322-325.
25. Salem I I, Alkhatib M, Najib N. LC–MS/MS determination of
betamethasone and its phosphate and acetate esters in human plasma after
sample stabilization. Journal of Pharmaceutical and Biomedical Analysis.
2011;56(1):983-991.
26. Patrício M, Ferreira F, Oliveiros B, Caramelo F. Comparing the
performance of normality tests with ROC analysis and confidence
intervals. Communications in Statistics - Simulation and Computation.
2017;46(10):7535-7551.
27. Clinical Pharmacology and Therapeutics. Statistical guide for
clinical pharmacology & therapeutics. Clin Pharmacol Ther.
2010;88(2):150-152.
28. Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic
changes. Clin Pharmacol Ther. 2016;100(1):53-62.
29. Costantine MM. Physiologic and pharmacokinetic changes in pregnancy.
Front Pharmacol. 2014;5:65.
30. Tracy TS, Venkataramanan R, Glover DD, Caritis SN, National
Institute for Child Health and Human Development Network of
Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism
(CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet
Gynecol. 2005;192(2):633-639.
31. Murphy D, West HF, Bethel AM. SOME ASPECTS OF THE METABOLISM AND
DISPOSITION OF BETAMETHASONE. Acta Endocrinol (Copenh). 1964;45:498-508.
32. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the
neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of
dexamethasone and methylprednisolone. Clinical Pharmacology &
Therapeutics. 2003;74(1):17-24.
33. Blanford AT, Murphy BE. In vitro metabolism of prednisolone,
dexamethasone, betamethasone, and cortisol by the human placenta. Am J
Obstet Gynecol. 1977;127(3):264-267.
34. Green B, Duffull SB. What is the best size descriptor to use for
pharmacokinetic studies in the obese? British Journal of Clinical
Pharmacology. 2004;58(2):119.
35. Gyamfi C, Mele L, Wapner RJ, et al. The effect of plurality and
obesity on betamethasone concentrations in women at risk for preterm
delivery. Am J Obstet Gynecol. 2010;203(3):219.e1-5.
Table 1 – Demographic, clinical and laboratory data from
singleton and twin pregnancies.